Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 3, 2014, Pages 290-298

  Erlandson, Kristine M ^a   O'riordan, MaryAnn ^b   Labbato, Danielle ^b   Mccomsey, Grace A ^b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

aging; immune activation; inflammation; monocyte activation; osteopenia

Indexed keywords

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MONOCYTES; OSTEOPOROSIS;

EID: 84894447824     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000005     Document Type: Article

References (43)

1. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937-946
2. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: Prevalence and associated factors. AIDS. 2008;22:395-402
3. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51:554-561
4. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791-1801
5. O'Brien CA. Control of RANKL gene expression. Bone. 2010;46:911-919
6. Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000;15:2-12
7. Weitzmann MN, Cenci S, Rifas L, et al. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and-independent mechanisms. J Bone Miner Res. 2001;16:328-337
8. Kawai T, Matsuyama T, Hosokawa Y, et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol. 2006;169:987-998
9. Pietschmann P, Grisar J, Thien R, et al. Immune phenotype and intracellular cytokine production of peripheral blood mononuclear cells from postmenopausal patients with osteoporotic fractures. Exp Gerontol. 2001; 36:1749-1759
10. Urushibara M, Takayanagi H, Koga T, et al. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum. 2004;50:794-804
11. Gibellini D, Borderi M, De Crignis E, et al. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol. 2007;79:1446-1454
12. Vikulina T, Fan X, Yamaguchi M, et al. Alterations in the immunoskeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A. 2010;107:13848-13853
13. Gazzola L, Bellistri GM, Tincati C, et al. Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIVinfected patients. J Transl Med. 2013;11:51
14. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: Causes and consequences. J Pathol. 2008;214:231-241
15. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010;201:1796-1805
16. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis. 2011;217:207-213
17. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203
18. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203: 780-790
19. Erlandson KM, Allshouse AA, Jankowski CM, et al. Association of functional impairment with inflammation and immune activation in HIV-1-infected adults on effective antiretroviral therapy. J Infect Dis. 2013
20. McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007;21:2473-2482
21. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129
22. Ross AC, O'Riordan MA, Storer N, et al. Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis. 2010;211:492-498
23. Cauley JA, Danielson ME, Boudreau RM, et al. Inflammatory markers and incident fracture risk in older men and women: The Health Aging and Body Composition Study. J Bone Miner Res. 2007;22:1088-1095
24. Barbour KE, Boudreau R, Danielson ME, et al. Inflammatory markers and the risk of hip fracture: The Women's Health Initiative. J Bone Miner Res. 2012;27:1167-1176
25. Redlich K, Smolen JS. Inflammatory bone loss: Pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012;11:234-250
26. Rothman MS, Bessesen MT. HIV infection and osteoporosis: Pathophysiology, diagnosis, and treatment options. Curr Osteoporos Rep. 2012;10: 270-277
27. Ofotokun I, McIntosh E, Weitzmann MN. HIV: Inflammation and bone. Curr HIV/AIDS Rep. 2012;9:16-25
28. Yin MT, McMahon DJ, Ferris DC, et al. Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2010;95:620-629
29. Hoy J, Grund B, Roediger M, et al. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART Body Composition substudy. J Bone Miner Res. 2013
30. Gutierrez OM, Farwell WR, Kermah D, et al. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int. 2011;22:1745-1753
31. Melendez MM, McNurlan MA, Mynarcik DC, et al. Endothelial adhesion molecules are associated with inflammation in subjects with HIV disease. Clin Infect Dis. 2008;46:775-780
32. Bosanska L, Michalsky D, Lacinova Z, et al. The influence of obesity and different fat depots on adipose tissue gene expression and protein levels of cell adhesion molecules. Physiol Res. 2010;59:79-88
33. Isoppo de Souza C, Rosa DD, Ettrich B, et al. Association of adipokines and adhesion molecules with indicators of obesity in women undergoing mammography screening. Nutr Metab (Lond). 2012;9:97
34. McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS. 2012;26:1371-1385
35. Padilla S, Masia M, Garcia N, et al. Early changes in inflammatory and pro-Thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis. 2011;11:40
36. Streeten EA, Brandi ML. Biology of bone endothelial cells. Bone Miner. 1990;10:85-94
37. Carano RA, Filvaroff EH. Angiogenesis and bone repair. Drug Discov Today. 2003;8:980-989
38. Tanaka Y, Morimoto I, Nakano Y, et al. Osteoblasts are regulated by the cellular adhesion through ICAM-1 and VCAM-1. J Bone Miner Res. 1995;10:1462-1469
39. Okada Y, Morimoto I, Ura K, et al. Cell-To-Cell adhesion via intercellular adhesion molecule-1 and leukocyte function-Associated antigen-1 pathway is involved in 1alpha,25(OH)2D3, PTH and IL-1alpha-induced osteoclast differentiation and bone resorption. Endocr J. 2002;49:483-495
40. Gao Y, Morita I, Kubota T, et al. Expression of adhesion molecules LFA-I and ICAM-I on osteoclast precursors during osteoclast differentiation and involvement of estrogen deficiency. Climacteric. 2000;3:278-287
41. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2009;49:1119-1127
42. Konishi M, Takahashi K, Yoshimoto E, et al. Association between osteopenia/ osteoporosis and the serum RANKL in HIV-infected patients. AIDS. 2005;19:1240-1241
43. Aloia JF. African Americans, 25-hydroxyvitamin D, and osteoporosis: A paradox. Am J Clin Nutr. 2008;88:545S-550S.